DOI: http://dx.doi.org/10.18203/2319-2003.ijbcp20194806

Neuropathic pain treatment between drug therapy and supplement effects

Mohammed Abdul Muttalib

Abstract


Neuropathic pain (NP) is a medical condition induced by diseases or lesions in the primary or inner cell systems that influence somatosensory nervous system buildings. Central NP, including backbone pain; multiple sclerosis, is recurrent. NP has an important impact on the life of patients and a strong economic impact on people and the society. some small neuropathy responds like a NSAID, aspirin and ibuprofen to an over-the-counter drug. More strong medicine (such as anti-depressants and serotonin-epinephrine reuptake inhibitors), anticonvulsants (pregabalin and gabapentin), and topical lidocaine-these are recognized as the most advanced neuropathical treatment-is also needed for other serious circumstances to increase ache leadership. Supplemental drugs, such as beta lipoic acid, acetyl-L-carnitine, benfotiamine, taurine and others, have been studied for neuropathic pain relieve under doctors to guarantee safe use and not bring any medicines that may interact with the dietary supplement. A medical procedure has been investigated for a neuro-lipoic pain relief. In specific, owing to the power of drug contrast with alternative products and owing to the effect of some drugs, it was considered that the drugs are (in spite of their side effects) more helpful and efficient to relieve neuropathic pain than the option, since neuropathic pain represents a serious illness and needs a more strong and effective therapy technology (particularly in severe cases).


Keywords


Acetyl-l-carnitine, Anti-depressants, Benfotiamine, Beta lipoic alcohol, Lidocaine, Neuropathic pain, Serotonin-epinephrine reuptake inhibitors

Full Text:

PDF

References


Treede RD, Jensen TS, Campbell JN, Cruccu G, Dostrovsky JO, Griffin JW, et al. Neuropathic pain: redefinition and a grading system for clinical and research purposes. Neurol. 2008;70(18):1630-5.

Dworkin RH, Backonja M, Rowbotham MC, Allen RR, Argoff CR, Bennett GJ, et al. Advances in neuropathic pain: diagnosis, mechanisms, and treatment recommendations. Arch Neurol. 2003 Nov 1;60(11):1524-34.

Attal N, Fermanian C, Fermanian J, Lantéri-Minet M, Alchaar H, Bouhassira D. Neuropathic pain: are there distinct subtypes depending on the aetiology or anatomical lesion?. Pain. 2008;138(2):343-53.

Langley PC, Van Litsenburg C, Cappelleri JC, Carroll D. The burden associated with neuropathic pain in Western Europe. J Medi Econo. 2013 Feb 1;16(1):85-95.

Lim EY, Kim YT. Food-derived natural compounds for pain relief in neuropathic pain. Bio Res Intl. 2016.

Gaskin DJ, Richard P. The economic costs of pain in the United States. J Pain. 2012 Aug 1;13(8):715-24.

Abbott CA, Malik RA, van Ross ER, Kulkarni J, Boulton AJ. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the UK. Diabe care. 2011;34(10):2220-4.

Finnerup NB, Haroutounian S, Kamerman P, Baron R, Bennett DL, Bouhassira D, et al. Neuropathic pain: an updated grading system for research and clinical practice. Pain. 2016;157(8):1599.

Sumizono M, Sakakima H, Otsuka S, Terashi T, Nakanishi K, Ueda K, et al. The effect of exercise frequency on neuropathic pain and pain-related cellular reactions in the spinal cord and midbrain in a rat sciatic nerve injury model. J pain Res. 2018;11:28.

Bayoumi AB, Ikizgul O, Karaali CN, Bozkurt S, Konya D, Toktas ZO. Antidepressants in Spine Surgery: A Systematic Review to Determine Benefits and Risks. Asia spine J. 2019.

Lee YC, Chen PP. A review of SSRIs and SNRIs in neuropathic pain. Exp Opin Pharmaco. 2010;11(17):2813-25.

Dukefoss TT, Kleggetveit IP, Helås T, Jørum E. Pain and small-fiber affection in hereditary neuropathy with liability to pressure palsies (HNPP). Scan J Pain. 2019 Sep 19.

Jensen TS, Madsen CS, Finnerup NB. Pharmacology and treatment of neuropathic pains. Curr Opin Neurol. 2009;22(5):467-74.

Chabal C, Jacobson L, Mariano A, Chaney E, Britell CW. The use of oral mexiletine for the treatment of pain after peripheral nerve injury. Anesthesiol. 1992;76(4):513-7.

Baron R, Binder A, Wasner G. Neuropathic pain: diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol. 2010;9(8):807-19.

Rojewska E, Piotrowska A, Popiolek-Barczyk K, Mika J. Botulinum toxin type A-a modulator of spinal neuron–glia interactions under neuropathic pain conditions. Toxins. 2018;10(4):145.

Pergolizzi JJ, LeQuang JA, Taylor JR, Raffa RB, Colucci D. The role of cannabinoids in pain control: the good, the bad, and the ugly. Min Anestesiol. 2018;84(8):955-69.

Chiechio S, Copani A, Nicoletti F, Gereau IV. L-Acetylcarnitine: A proposed therapeutic agent for painful peripheral neuropathies. Curr Neuropharmacol. 2006;4(3):233-7.

Notartomaso S, Mascio G, Bernabucci M, Zappulla C, Scarselli P, Cannella M, et al. Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain. Mol pain. 2017;13:1744806917697009.

Onysko M, Legerski P, Potthoff J, Erlandson M. Targeting neuropathic pain: consider these alternatives. J Fam Pract. 2015;64(8):470-5.

Chiechio S, Copani A, Nicoletti F, Gereau IV. L-Acetylcarnitine: A proposed therapeutic agent for painful peripheral neuropathies. Curr Neuropharmacol. 2006;4(3):233-7.

Chiechio S, Copani A, Gereau RW, Nicoletti F. Acetyl-L-carnitine in neuropathic pain. CNS drugs. 2007;21(1):31-8.

Vanotti A, Osio M, Mailland E, Nascimbene C, Capiluppi E, Mariani C. Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. CNS drugs. 2007;21(1):3-12.

Baute V, Zelnik D, Curtis J, Sadeghifar F. Complementary and Alternative Medicine for Painful Peripheral Neuropathy. Currt Treatt Opt Neurol. 2019;21(9):44.

Packer L, Witt EH, Tritschler HJ. Alpha-lipoic acid as a biological antioxidant. Free Rad Bio Medi. 1995;19(2):227-50.

Costantino M, Guaraldi C, Costantino D, De Grazia S, Unfer V. Peripheral neuropathy in obstetrics: efficacy and safety of a-lipoic acid supplementation. Eur Rev Med Pharmacol Sci. 2014;18(18):2766-71.

Mostacci B, Liguori R, Cicero AF. Nutraceutical approach to peripheral neuropathies: evidence from clinical trials. Curr Drug Metab. 2018;19(5):460-8.

Battisti E, Albanese A, Guerra L, Argnani L, Giordano N. Alpha lipoic acid and superoxide dismutase in the treatment of chronic low back pain. Eur J Phys Rehabil Med. 2013;49(5):659-4.

Papanas N, Ziegler D. Efficacy of α-lipoic acid in diabetic neuropathy. Exp Opin Pharmaco. 2014;15(18):2721-31.

Nacitarhan C, Minareci E, Sadan G. The effect of benfotiamine on mu-opioid receptor mediated antinociception in experimental diabetes. Exp Clin Endocrinol Diabe. 2014;122(03):173-8.

Stracke H, Gaus W, Achenbach U, Federlin K, Bretzel RG. Benfotiamine in diabetic polyneuropathy (BENDIP): results of a randomised, double blind, placebo-controlled clinical study. Exp Clin Endocrinol Diabe. 2008;116(10):600-5.

Sánchez-Ramírez GM, Caram-Salas NL, Rocha-González HI, Vidal-Cantú GC, Medina-Santillán R, Reyes-García G, et al. Benfotiamine relieves inflammatory and neuropathic pain in rats. Eur J Pharmacol. 2006;530(1-2):48-53.